文献速递基础与转化研究新药、器械与细胞基因治疗研发

CAR-T细胞疗法选择性清除骨髓纤维化中驱动疾病的突变钙网蛋白细胞

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.
PubMed 文献 · Sci Transl Med · 2026-07-01

本研究开发了靶向突变钙网蛋白(mutCALR)的CAR-T细胞疗法,在体外和体内实验中选择性清除骨髓纤维化患者的mutCALR+干细胞而不影响健康干细胞,并在mutCALR白血病异种移植模型中改善生存。研究还建立了人源「嵌合体」模型模拟纤维化骨髓微环境,显示CAR-T细胞杀伤效力未降低,并开发了增强CD34+细胞表面mutCALR表达的方法以提升靶向效果。

要点

  • 靶向mutCALR的CAR-T细胞可选择性清除骨髓纤维化患者的mutCALR+干细胞。
  • 在纤维化微环境的人源嵌合体模型中,CAR-T细胞杀伤效力未下降。
  • 增强CD34+细胞表面mutCALR表达可提升CAR-T细胞靶向效果。

核心结论

  • 靶向mutCALR的CAR-T细胞疗法有潜力根除mutCALR驱动的恶性肿瘤。

研究设计与样本

  • 研究在体外和体内评估靶向mutCALR的CAR-T细胞疗法。
  • 使用骨髓纤维化患者样本、mutCALR白血病异种移植模型及人源「嵌合体」模型。

主要发现

  • CAR-T细胞选择性清除骨髓纤维化患者的mutCALR+干细胞,不影响健康干细胞。
  • 在mutCALR白血病异种移植模型中,CAR-T细胞疗法改善生存。
  • 在模拟纤维化骨髓的人源「嵌合体」模型中,CAR-T细胞杀伤靶细胞的效力未降低。
  • 增强加速期/急变期MPN患者CD34+细胞表面mutCALR表达可提升CAR-T细胞靶向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeted immunotherapies have revolutionized outcomes for lymphoid malignancies, but success in myeloid neoplasms is limited by the lack of amenable targets and immunologically hostile tumor microenvironment (TME). Myeloproliferative neoplasms (MPNs) are chronic myeloid blood cancers, a third of which are driven by mutations in calreticulin. Calreticulin mutant protein (mutCALR) binds and activates thrombopoietin receptor (TpoR) and results in the display of the mutCALR-TpoR complex on the extracellular membrane of disease-driving cells, thus exposing a therapeutic vulnerability. Here, we present a chimeric antigen receptor T cell (CAR T cell) therapy that specifically targets mutCALR+ cells, both in vitro and in vivo. The CAR T cell therapy selectively depleted mutCALR+ stem cells in samples from patients with myelofibrosis without affecting healthy stem cells and improved survival in mutCALR leukemia xenograft models. To mimic myelofibrotic marrow, we developed a human "chimeroid" model and showed no decrease in the potency of CAR T cell-mediated target cell killing even in a fibrotic TME. We also devised a method to boost the cell surface expression of mutCALR in CD34+ cells isolated from patients with accelerated/blast phase MPNs (defined as >10% blasts in the peripheral blood or bone marrow), enhancing CAR T cell targeting. This study presents a therapeutic strategy with potential to eradicate mutCALR-driven malignancies and highlights an innovative strategy to evaluate blood cancer-targeting immunotherapies in a relevant TME.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Rampotas A, Wong ZC, Gannon I, et al. CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis. Sci Transl Med. 2026. PMID: 42384776. doi:10.1126/scitranslmed.adz3553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。